Outcomes with two different schedules of bortezomib, melphalan, and prednisone (VMP) for previously untreated multiple myeloma: matched pair analysis using long-term follow-up data from the phase 3 VISTA and PETHEMA/GEM05 trials
Crossref DOI link: https://doi.org/10.1007/s00277-016-2835-3
Published Online: 2016-10-14
Published Print: 2016-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Mateos, Maria-Victoria
Oriol, Albert
Martínez-López, Joaquín
Teruel, Ana-Isabel
Bengoechea, Enrique
Palomera, Luis
de Arriba, Felipe
Esseltine, Dixie-Lee
Cakana, Andrew
Pei, Lixia
van de Velde, Helgi
Miguel, Jesus San
License valid from 2016-10-14